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Disease progression in multiple myeloma (MM) can
occur as a biochemical relapse (an increase in monoclonal
component without end-organ damage) or as a clinical
relapse (a proliferation of plasma cells accompanied by
MM-related symptoms). The International Myeloma
Working Group recommends that treatment should be
initiated in the presence of a clinical relapse or in case of a
rapid increase in the monoclonal component. The suit-
ability of early treatment at the occurrence of biochemical
relapse is still a matter of debate.
Although continuous therapy prolongs overall survival
(OS) as compared to fixed-duration treatment1–3, the
salvage regimen bortezomib-dexamethasone (Vd, a stan-
dard of care and a platform for several triplet regimens) is
usually administered for a fixed number of cycles4,5.
Here we present the results of a multicenter, rando-
mized phase II study aiming at evaluating efficacy and
safety of either Vd maintenance or Vd retreatment at the
occurrence of biochemical relapse as compared to stan-
dard observation in MM patients who received a
bortezomib-based salvage regimen at relapse.
Patient eligibility, study design and statistical analysis
are summarized in the Supplementary Appendix. Briefly,
patients with relapsed/refractory (RR)MM (1–3 previous
therapies) treated with a bortezomib-based regimen as
last line of therapy without evidence of progression were
randomized to: continuous treatment with subcutaneous
bortezomib (1.3 mg/m2; days 1,15) and oral dex-
amethasone (20 mg; days 1, 2, 15, 16) every 28 days until
progression (arm A); observation until clinical relapse as
per standard of care (arm B); six 28-day cycles of sub-
cutaneous bortezomib (1.3 mg/m2; days 1, 8, 15, 22) and
oral dexamethasone (40 mg; days 1, 8, 15, 22) at the
occurrence of biochemical relapse. The primary objective
was to determine the time to progression (TTP), calcu-
lated as either the time from enrollment to biochemical
relapse (TTBR) or the time from enrollment to clinical
relapse (TTCR). This trial was conducted in accordance
with the Declaration of Helsinki and the principles of
Good Clinical Practice and was registered at ClinicaTrials.
gov (NCT01913730).
We analyzed 58 patients (median age: 70 years) enrolled
from 21 Nov 2013 to 16 Mar 2017 and randomized to the
three arms (A= 15, B= 20, C= 23, Supplementary Fig.
S1; see Supplementary Table S1 for patient character-
istics). On 22 Jul 2015, the protocol was amended: the arm
A (Vd maintenance) was closed due to low speed of
enrollment and the sample size was reduced.
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In arm A, all patients (15/15) started Vd maintenance
(median number of 11 maintenance cycles). In arm B, 18
patients (90%) experienced a biochemical relapse, in all
cases followed by a clinical relapse, and started a sub-
sequent line of therapy. In arm C, 21 patients had a bio-
chemical relapse: 17 started therapy with Vd (median
number of cycles: 6), while 4 patients did not (2 con-
comitant clinical relapses; 1 death; 1 consent withdrawal);
19 patients (83%) had a subsequent clinical relapse.
In arm A, the best response with Vd maintenance was at
least a complete response (≥CR) in 20% of patients, very
good partial response (VGPR) in 13% and PR in 20%
(Supplementary Table S2); 33% of patients improved by at
least 1 category the response achieved with the previous
therapy.
In arm C, Vd after the occurrence of a biochemical
relapse resulted into an overall response rate (ORR) of
30% (PR, 6%; VGPR, 24%), with 82% of patients achieving
at least a stable disease (SD), while 18% of patients pro-
gressed while on therapy (PD).
After a median follow-up of 41 months, TTBR was
longer in patients receiving Vd maintenance (arm A,
18.2 months) than in patients who were observed until the
occurrence of biochemical relapse (arm B, 4.9 months;
arm C, 8.4 months; Fig. 1). TTCR was longer in patients
treated with Vd maintenance (arm A, 22.1 months) or Vd
at biochemical relapse (arm C, 20.3 months) than in
patients under observation only (arm B, 9.5 months),
being similar in the two experimental arms (A, C).
The median second progression-free survival (2nd PFS)
was 20.5, 11.8 and 8.2 months in arms A, B and C,
respectively.
A longer median OS was reported with Vd maintenance
(arm A, 45.1 months), as compared to observation (arm B,
Fig. 1 Survival outcomes. Time to biochemical relapse (a), time to clinical relapse (b) and overall survival (c) in the examined population. TTBR time
to biochemical relapse, TTCR time to clinical relapse, OS overall survival, ARM A bortezomib and dexamethasone until progression, ARM B observation
until clinical relapse, ARM C early retreatment at biochemical relapse with bortezomib and dexamethasone.
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32.8 months) or Vd at biochemical relapse (arm C,
31.7 months), although this difference was not statistically
significant.
Treatment was well tolerated, with limited grade 3–4,
treatment-related adverse events (AEs; arm A 20%, arm B,
6%). Peripheral neuropathy (PN), mainly of grade 1–2,
occurred in 20 and 12% of patients in arms A and C,
respectively. Treatment discontinuation due to AEs was
reported in 20 and 6% of patients in arms A and C,
respectively (Table 1).
Continuous treatment is a standard approach in newly
diagnosed (ND)MM and RRMM patients. In NDMM,
continuous lenalidomide is a standard of care1,6. Main-
tenance therapy with the oral proteasome inhibitor ixa-
zomib proved to be an effective strategy in delaying
disease progression after ASCT2. Although bortezomib
maintenance can extend PFS and OS in both transplant-
eligible and -ineligible patients3,7, bortezomib is usually
administered for a limited number of cycles, primarily due
to the risk of PN and the inconvenience for patients
attending hospital for subcutaneous administration6–10.
We hypothesized that the use of continuous Vd, in
patients sensitive to a bortezomib-based salvage regimen
as last line of therapy, would maintain, and even deepen,
the previously achieved depth of response, ultimately
delaying disease progression in comparison with obser-
vation. In our study, the administration of Vd main-
tenance delayed by approximately 1 year TTBR (18.2 vs.
4.9 months) and TTCR (22.1 vs. 9.5 months), as compared
to the control arm, in which patients were observed until
the occurrence of clinical progression as per standard of
care. Importantly, maintenance therapy did not negatively
impact the efficacy of the subsequent lines of therapy, as
shown by the longer median 2nd PFS (20.5 months) in the
maintenance arm compared to that in the observation
arm (11.8 months; Supplementary Table S3)1,2,7. Vd
maintenance was well tolerated, with a limited rate of PN
(12% all grades; 6% grades 3–4). These findings are con-
sistent with a phase 2 study that tested Vd maintenance in
RRMM, reporting an ORR of 34.5% and a median TTP of
17 months11. These results are of interest in the context of
novel bortezomib-based combinations, such as dar-
atumumab-Vd, in which bortezomib is administered only
for 8 cycles5.
Salvage therapy is currently recommended in case of
clinical relapse. However, this strategy is in contrast with
the current definition of MM, which includes not only
signs and symptoms of a clinically overt MM, but also
markers predictive of an early imminent progression,
prompting a therapeutic intervention in asymptomatic
patients to prevent the development of MM-related
comorbidities12. In a Spanish trial, the median interval
between biochemical and clinical relapse was
5.1 months13. Furthermore, there is evidence that bio-
chemical relapse precedes the onset of a clinical relapse by
several months13, and that early retreatment at bio-
chemical relapse, rather than at clinical relapse, can delay
disease progression and the onset of significant myeloma-
related comorbidities, thus improving patients’ quality of
life14.
To our knowledge, this is the first randomized study
that prospectively evaluated the efficacy and safety of early
treatment at biochemical relapse in MM.
Early intervention with Vd induced disease stability or
better in 82% of the treated patients and delayed clinical
progression by ~11 months, as compared to observa-
tion until clinical relapse (20.3 vs. 9.5 months). These
results confirmed the findings of previous studies. In
the REBOUND trial, retreatment with a bortezomib-
based regimen induced an ORR of 71% and a median
PFS of 15 months. Retreatment with Vd was well tol-
erated, with a limited rate of PN15. The evidence gen-
erated by our study represents a proof-of-concept,
suggesting that early retreatment in MM patients who
previously benefited from a bortezomib-based therapy
—with the aim of preventing MM-related anemia, bone
lesions, renal failure and hypercalcemia – is feasible and
effective.
Table 1 Treatment-related adverse events during the
study treatment.

















At least 1 event 13 0 47 0
Anemia 7 0 29 0
Neutropenia 7 0 12 0
Thrombocytopenia 7 0 12 0
Non-hematologic
At least 1 event 33 20 53 6
Cardiologic 0 0 6 0
Vascular 7 7 12 0
Infection 13 7 24 6
Nervous 20 7 18 0
Peripheral neuropathy 20 7 12 0
Gastrointestinal 13 0 6 0
Discontinuation due
to adverse events
20 – 6 –
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Limitations of this study were the long enrollment time
and the small sample size of enrolled patients, which
limited the statistical significance of the comparisons.
Also, the small sample size precluded subgroup analyses
to understand whether a specific subset of patients, as
those with a suboptimal response (<CR), could benefit
more from continuous therapy or early retreatment with
the same drug than those who had achieved CR (or vice
versa). Despite these limitations, we were able to capture a
clinically meaningful difference in TTBR and TTCR
between the experimental arms (A, maintenance, and C,
retreatment) and the control arm (observation, B). The
study was specifically designed to compare each one of the
experimental arms to the control arm, but not to one
another. Consequently, we are unable to draw definite
conclusions on the best bortezomib-based strategy to
delay clinical relapse, whether a continuous, gentler
approach after the induction phase or a close observation
followed by early bortezomib retreatment at the occur-
rence of biochemical relapse, in order to allow patients a
treatment-free period.
In conclusion, we demonstrated that, in RRMM treated
with a bortezomib-based salvage therapy, maintenance
therapy with Vd or early retreatment with Vd at the
occurrence of biochemical relapse were safe and effective
strategies to delay clinical progression without negatively
affecting the efficacy of subsequent lines of therapy.
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